Bioinformatics Seminar
Time: 11AM
Venue: Davis Auditorium and Online
24 February 2026
Unravelling the Cellular Landscape of Response to mIDH Inhibition in Glioma
Montana SpiteriWEHI
Mutant IDH (mIDH) gliomas are infiltrative and heterogeneous brain tumours characterised by marked cellular plasticity and therapeutic resistance. Although mIDH inhibitors represent a more targeted and promising therapeutic strategy that reshapes the tumour cell-state landscape, the determinants of response remain incompletely understood. Using perioperative tumour samples collected before and after mIDH inhibitor treatment and profiled at single-cell and spatial resolution, we define state-specific responses to mIDH inhibition. By integrating single-cell transcriptomic and metabolic analyses, we identify candidate regulatory programs associated with differential sensitivity to treatment. Notably, we uncover an intermediate tumour cell population that correlates strongly with therapeutic response, implicating cellular plasticity as a key mediator of vulnerability. Together, these findings position tumour adaptability as a central determinant of response to mIDH inhibition in glioma.